ProPhase Labs, Inc. Total Contract Liability
ProPhase Labs, Inc. (PRPH) had Total Contract Liability of $2.10 million as of 2025-12-31, per its 10-K filed 2026-06-01.
Financial Statements › Balance Sheet › Liabilities
us-gaap:ContractWithCustomerLiability · last filed 2026-06-01
- 2025-12-31: Contract with Customer, Liability $2.10M.
- 2024-12-31: Contract with Customer, Liability $2.50M.
- 2023-12-31: Contract with Customer, Liability $3.50M.
- 2022-12-31: Contract with Customer, Liability $3.60M.
| Period end | Contract with Customer, Liability |
|---|---|
| 2025-12-31 | $2.10M 10-K · filed 2026-06-01 |
| 2024-12-31 | $2.50M 10-K · filed 2026-06-01 |
| 2023-12-31 | $3.50M 10-K · filed 2025-04-01 |
| 2022-12-31 | $3.60M 10-K · filed 2024-03-29 |
| 2022-09-30 | $3.88M 10-Q · filed 2022-11-10 |
| 2022-06-30 | $3.41M 10-Q · filed 2022-08-12 |
| 2022-03-31 | $3.10M 10-Q · filed 2022-05-13 |
| 2021-12-31 | $2.94M 10-K · filed 2023-03-29 |
| 2021-09-30 | $1.62M 10-Q · filed 2021-11-12 |
| 2021-06-30 | $233.00K 10-Q · filed 2021-08-13 |
| 2021-03-31 | $278.00K 10-Q · filed 2021-05-14 |
| 2020-12-31 | $331.00K 10-K · filed 2022-03-31 |
| 2020-09-30 | $319.00K 10-Q · filed 2020-11-19 |
| 2020-06-30 | $221.00K 10-Q · filed 2020-08-11 |
| 2020-03-31 | $205.00K 10-Q · filed 2020-05-12 |
| 2019-12-31 | $214.00K 10-K · filed 2021-03-31 |
| 2019-09-30 | $247.00K 10-Q · filed 2019-11-12 |
| 2019-06-30 | $302.00K 10-Q · filed 2019-08-12 |
| 2019-03-31 | $119.34M 10-Q · filed 2019-05-14 |
| 2018-12-31 | $206.00K 10-K · filed 2020-03-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) | United States | $0.005B | |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |